NYU Langone IBD Center celebrates two years of transforming lives

A complex, chronic, and debilitating condition, inflammatory bowel disease (IBD) affects roughly 3 million Americans, including those with Crohn’s disease and ulcerative colitis.

FUSE: Revolutionizing the analysis of gene mutations

Our study introduces a new tool called FUSE (Functional Substitution Estimation) that helps scientists better understand how changes in genes affect proteins.

October 25, 2024

BridgeBio’s $250M offering; ViiV’s PhI data for ultra-long-acting HIV treatment

Plus, news about Viking Therapeutics, Arcutis Biotherapeutics, Akari and Peak Bio: BridgeBio’s stock sale: The company announced plans to raise $250 million the same day

March 6, 2024

GLP-2 Analog Reduces Need for Parenteral Support in Patients With Rare GI Condition

WASHINGTON — Apraglutide, an investigational long-acting synthetic GLP-2 analog, reduced the need for parenteral support in patients with short bowel syndrome and intestinal failure (SBS-IF),

May 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.